Prognia
Drug Database
🇪🇺EU · EMAApplication withdrawnATC: L01EOrphan Medicine

Febseltiq(Infigratinib monophosphate)

Cholangiocarcinoma

Marketing Authorisation Holder: Helsinn Birex Pharmaceuticals Ltd

INN: infigratinib

Indication

Treatment of cholangiocarcinoma.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Febseltiq — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.